LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE THROMBOSIS TREATMENT DRUG

• US 20170224812A1
• Filed: 08/04/2015
• Published: 08/10/2017
• Est. Priority Date: 08/04/2014
• Status: Active Grant

• Current Assignee: Nitto Denko Corporation
• Original Assignee: Nitto Denko Corporation
• Inventors: SHISHIDO, Takuya, ASARI, Daisuke, MATSUSHITA, Kyohei, HORI, Mitsuhiko
• Granted Patent: US 10,456,464 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/542 oral/gastrointestinal
• CPC Class Codes: A61K 2039/543 intranasal
• CPC Class Codes: A61K 2039/55511 Organic adjuvants
• CPC Class Codes: A61K 2039/55588 Adjuvants of undefined constitution
• CPC Class Codes: A61K 2039/575 humoral response
• CPC Class Codes: A61K 31/235 having an aromatic ring attached to a carboxyl group
• CPC Class Codes: A61K 31/4465 only substituted in position 4
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 31/4709 Non-condensed quinolines and containing further heterocyclic rings
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 45/00 Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention aims to provide a humoral immunity induction-promoting composition and a vaccine pharmaceutical composition which can universally be used for inducing humoral immunity to various antigens and exert a high antibody production inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing humoral immunity containing an antigen and a humoral immunity induction promoter whose active ingredient is a thrombosis treatment drug.

Claims

1. A humoral immunity induction-promoting composition, comprising:

a humoral immunity induction promoter whose active ingredient is a thrombosis treatment drug.

2. The humoral immunity induction-promoting composition according to claim 1,

wherein the thrombosis treatment drug is a thrombogenesis-suppressing compound.

3. The humoral immunity induction-promoting composition according to claim 2,

wherein the thrombogenesis-suppressing compound is at least one of an anticoagulant or an antiplatelet,

the anticoagulant being at least one selected from the group consisting of heparin, dalteparin, fondaparinux, antissasin, TAP (tick anticoagulant peptide), rivaroxaban, apixaban, edoxaban, betrixaban, eribaxaban, YM-150, LY-517717, TAK-442, ximelagatran, dabigatran, argatroban, hirudin, nafamostat, camostat, gabexate, warfarin, and coumarin,

the antiplatelet being at least one selected from the group consisting of abciximab, eptifibatide, and tirofiban.

4. A vaccine pharmaceutical composition for inducing humoral immunity, comprising:

an antigen; and

the humoral immunity induction-promoting composition according to claim 1.

5. The vaccine pharmaceutical composition according to claim 4, which is administered to a body surface.

6. The vaccine pharmaceutical composition according to claim 4, which is administered by intradermal injection, subcutaneous injection, or intramuscular injection.

7. A method for promoting humoral immunity induction in a subject in need thereof, comprising:

administering to the subject an effective amount of a humoral immunity induction promoter comprising a thrombosis treatment drug.

8. The method for promoting humoral immunity induction according to claim 7,

wherein the thrombosis treatment drug is a thrombogenesis-suppressing compound.

9. The method for promoting humoral immunity induction according to claim 8,

wherein the thrombogenesis-suppressing compound is at least one of an anticoagulant or an antiplatelet, and

the anticoagulant is at least one selected from the group consisting of heparin, dalteparin, fondaparinux, antissasin, TAP (tick anticoagulant peptide), rivaroxaban, apixaban, edoxaban, betrixaban, eribaxaban, YM-150, LY-517717, TAK-442, ximelagatran, dabigatran, argatroban, hirudin, nafamostat, camostat, gabexate, warfarin, and coumarin, and

the antiplatelet is at least one selected from the group consisting of abciximab, eptifibatide, and tirofiban.

10. A method for promoting humoral immunity induction in a subject in need thereof, comprising:

administering to the subject an effective amount of a vaccine pharmaceutical composition for inducing humoral immunity, which comprises

an antigen; and

a humoral immunity induction promoter comprising a thrombosis treatment drug.

11. The method for promoting humoral immunity induction according to claim 10, wherein the vaccine is administered to a body surface.

12. The method for promoting humoral immunity induction according to claim 10, wherein the vaccine is administered by intradermal injection, subcutaneous injection, or intramuscular injection.